Skip to main content
. Author manuscript; available in PMC: 2019 Dec 6.
Published in final edited form as: Psychopharmacology (Berl). 2019 Jul 13;236(12):3593–3599. doi: 10.1007/s00213-019-05331-y

Fig. 3.

Fig. 3

Attenuation of the development of nicotine CPP by α7 nAChR Type II PAM PNU120596. Mice were administered saline (s.c.) or nicotine (0.5 mg/kg; s.c.) for 3 days. Nicotine administration produced a significant CPP in mice pre-treated with vehicle. The α7 Type II PAM PNU120596 (0.3, 1, and 3 mg/kg; i.p.) reduced nicotine reward as measured by the CPP test at both doses tested. Asterisk denotes p < 0.05 from vehicle-vehicle. Number sign denotes p < 0.05 from nicotine control. Each point represents the mean ± SEM of n = 9–15 mice per group